tirzepatide surpass-4 versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial Frias_Tirzepatide: Overview of SURPASS Trials

Eligibility restrictions apply, and this program is not available to Medicare, Medicaid, or federal healthcare program participants

The dose that created a significant caloric deficit at 250 pounds may not create the same deficit at 200 pounds

You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first

Can You Lower the Dose After Reaching Your Goal

Note: CVS Caremark removed Zepbound for both weight loss AND sleep apnea indications in 2025, so the OSA pathway won't work with Aetna's standard formulary

This equalizes pressure and makes drawing the liquid easier